BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pulmicort (Budesonide) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pulmicort (Budesonide)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03250975-4382@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Pulmicort (Budesonide): Phase 1/2 readout est. (NCT03250975)
DESCRIPTION:Pulmicort (Budesonide)\, phase 1/2.\nStudy: Incidence of Acute 
 Laryngeal Injury Following Endotracheal Intubation\nEstimated primary comp
 letion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/budesonide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03250975
URL:https://assetmemo.bio/drug/budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684105-4382@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pulmicort (Budesonide): Phase na readout est. (NCT07684105)
DESCRIPTION:Pulmicort (Budesonide)\, phase na.\nStudy: Treatment of Dysphag
 ia in Patients With Dystrophic Epidermolysis Bullosa With Budesonide: a Re
 trospective Bicentric Study Nice - Paris St Louis / Necker (EBUDE Study)\n
 Estimated primary completion: 31 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/budesonide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07684105
URL:https://assetmemo.bio/drug/budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06334575-4382@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pulmicort (Budesonide): Phase 4 readout est. (NCT06334575)
DESCRIPTION:Pulmicort (Budesonide)\, phase 4.\nStudy: Molecular Signatures 
 Associated With Response to ICS Treatment in Patients With COPD Stratified
  by Eosinophil Levels\nEstimated primary completion: December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/budesonide#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06334575
URL:https://assetmemo.bio/drug/budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05509933-4382@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Pulmicort (Budesonide): Phase 3 readout est. (NCT05509933)
DESCRIPTION:Pulmicort (Budesonide)\, phase 3.\nStudy: Budesonide Prophylaxi
 s for Engraftment Syndrome After Hematopoietic Cell Transplantation\nEstim
 ated primary completion: 30 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/budesonide#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05509933
URL:https://assetmemo.bio/drug/budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06719622-4382@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pulmicort (Budesonide): Phase 2/3 readout est. (NCT06719622)
DESCRIPTION:Pulmicort (Budesonide)\, phase 2/3.\nStudy: Evaluation of the E
 fficacy of Local Budesonide Treatment in Children with Crohn's Disease Loc
 ated in the Esophagus And/or Stomach And/or Duodenum\nEstimated primary co
 mpletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/budesonide#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06719622
URL:https://assetmemo.bio/drug/budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05839756-4382@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20280225
DTEND;VALUE=DATE:20280226
SUMMARY:Pulmicort (Budesonide): Phase na readout est. (NCT05839756)
DESCRIPTION:Pulmicort (Budesonide)\, phase na.\nStudy: Predicting Post Extu
 bation Stridor After Maxillomandibular Fixation\nEstimated primary complet
 ion: 25 February 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/budesonide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05839756
URL:https://assetmemo.bio/drug/budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07877519-4382@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pulmicort (Budesonide): Phase na readout est. (NCT07877519)
DESCRIPTION:Pulmicort (Budesonide)\, phase na.\nStudy: Conscious Sedation V
 ersus General Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial Fi
 brillation\nEstimated primary completion: June 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/budesonide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07877519
URL:https://assetmemo.bio/drug/budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07386873-4382@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pulmicort (Budesonide): Phase na readout est. (NCT07386873)
DESCRIPTION:Pulmicort (Budesonide)\, phase na.\nStudy: Position-Directed Bu
 desonide Nasal Drops for CRS-associated Olfactory Dysfunction\nEstimated p
 rimary completion: 31 December 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/budesonide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07386873
URL:https://assetmemo.bio/drug/budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07934420-4382@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20290730
DTEND;VALUE=DATE:20290731
SUMMARY:Pulmicort (Budesonide): Phase 3 readout est. (NCT07934420)
DESCRIPTION:Pulmicort (Budesonide)\, phase 3\, Asthma.\nStudy: An Efficacy 
 and Safety Study to Assess an Inhaled\, Fixed-dose\, Budesonide/Formoterol
  Fumarate in Participants Aged 4 to Less Than 12 Years of Age With Moderat
 e Persistent Asthma\nEstimated primary completion: 30 July 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/budesonide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07934420
URL:https://assetmemo.bio/drug/budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855043-4382@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pulmicort (Budesonide): Phase 1/2 readout est. (NCT06855043)
DESCRIPTION:Pulmicort (Budesonide)\, phase 1/2.\nStudy: Little Lungs Study\
 nEstimated primary completion: August 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/budesonide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06855043
URL:https://assetmemo.bio/drug/budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860542-4382@assetmemo.bio
DTSTAMP:20261121T005611Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Pulmicort (Budesonide): Phase 2 readout est. (NCT06860542)
DESCRIPTION:Pulmicort (Budesonide)\, phase 2.\nStudy: Inhaled Budesonide fo
 r REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneum
 onitis\nEstimated primary completion: 1 December 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/budesonide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06860542
URL:https://assetmemo.bio/drug/budesonide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
